Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Cataract
  • Dry Eye Disease
  • Dry Eye Syndrome
  • Evaporative Dry Eye
  • Phacoemulsification
Type
Interventional
Phase
Phase 3
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Eligible patients will be enrolled and randomly assigned by a computer generated randomization list in a 1:1:1 ratio to the intervention groups (2) or the control group. After cataract surgery, all groups will be given a topical steroid-antibiotic (tobramycin 0.3% and dexamethasone acetate 0.1%) commercially available and commonly used by ophthalmologists worldwide postoperatively, in a 3-week tapered regimen (every 2 hours the first day, then every 4 hours for 6 days, then 3 times a day for 1 week and twice a day for 1 week). The 2 study groups will be also prescribed lubricant eye drops from the postoperative day 7 containing sodium hyaluronate 0.1% (in 2 different commercially available formulations) to instill 4 times daily for the following 3 months. Study group patients will be instructed to instill the lubricant eyedrops at least 10 minutes after the tobramycin-dexamethasone eyedrops. At postoperative visits, patients will be asked about compliance with the assigned treatment.Masking: Double (Investigator, Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 99 years
Gender
Both males and females

Description

A prospective randomized study has been designed to assess and characterize OSD/DE in consecutive patients presenting for cataract surgery evaluation and to identify eventual changes on biomarkers of the tear film of the same population postoperatively. At the same time, 2 different postoperative ey...

A prospective randomized study has been designed to assess and characterize OSD/DE in consecutive patients presenting for cataract surgery evaluation and to identify eventual changes on biomarkers of the tear film of the same population postoperatively. At the same time, 2 different postoperative eye drops regimen will be evaluated in order to determine its impact on postoperative OSD/DE. All group of patients will be subjected to Dry Eye assessment using diagnosis criteria and methodologies recommended by the 2017 Dry Eye Workshop (DEWS II) (2), which includes the assessment of a battery of symptoms (OSDI questionnaire), signs (tear meniscus height, corneal and conjunctival lissamine green/fluorescein staining), laboratory tests (Schirmer I, TBUT assessment, tear osmolarity, tear MMP-9, meibography, ocular redness, lipid layer thickness) and physical examination (lid, meibum gland assessment). This assessment will be carried out in all groups preoperative and at postoperative week 4 and postoperative week 12. Altogether, by identifying definite changes either in novel tear film biomarkers or non invasive ocular tests of patients subjected to cataract surgery, we expect to contribute to the understanding of the pathophysiology of the OSD and Dry Eye associated to cataract surgery and to give lights on the utility of those changes as biomarkers in diagnosis and therapy assessment in these conditions committing the ocular surface. The research hypothesis is that there is a high prevalence of ocular surface dysfunction among patients presenting for cataract surgery as measured by point-of-care objective tear tests and cataract surgery results in altered ocular surface in a major fraction of patients. Dry eye symptoms are not necessary associated with objective signs in the ocular surface, but are less in the group of patients treated with associated lubricant eyedrops postoperatively. Patients more symptomatic in the postoperative period tend to have multiple preoperative OSD/DE biomarkers altered. Consecutive patients presenting for cataract surgery evaluation will be recruited at the Fundacion Oftalmologica Los Andes (FOLA) Ophthalmology Clinic (Santiago, Chile). Patients will be eligible according to inclusion and exclusion criteria indicated. Eligible patients will be invited to participate voluntary in the study. The study will comprise three groups with 30-35 patients per group. Dry eye patients will be diagnosed according to TFOS DEWS II report and to the recommendations of the Dry Eye Workshop of 2017. It will basically consist of: a) patient history: symptoms and signs (e.g. ocular irritation, dryness or foreign body sensation, redness, etc), exacerbating conditions, duration of symptoms, etc., will be obtained by using the Ocular Surface Disease Index (OSDI). b) physical examination: visual acuity measurement, external examination and slit lamp biomicroscopy (tear film, tear meniscus, eyelashes, eyelid margins, conjunctiva, cornea, lens and retina). c) Diagnostic tests: Tear film osmolarity (using Tearlab), Tear film MMP-9 levels (using InflammaDry). Non-invasive tests will be performed using Keratograph 5M, which includes: non-invasive tear film break up time tear meniscus height, lipid layer thickness, ocular redness and meibography. The study will comprise three groups. Each group will comprise 30-35 patients. Each of the 100 patients will be featured by a list of clinical parameters (ocular signs and symptoms and laboratory tests used conventionally for Dry Eye diagnostic). It is expected to observe differences in parameters before and after cataract surgery and between the control group and the two interventional groups. Association of those differences with the type of postoperative regimen will be defined statistically by using Student t-test and ANOVA for parametric data and U-test of Mann-Whitney for non-parametric data (p<0.05 will be taken as significant). Altogether, it is expected that such a multiplicity of signs and symptoms will give valuable data on specificities of Dry Eye after cataract surgery. All the participant surgeons will have a summary document of the inclusion and exclusion criteria and a flowchart of the patient's enrollment process to improve compliance. The data will be stored on an external digital platform and only the data analyst will have access to it. In addition, there will be written records of each enrolled patient.

Tracking Information

NCT #
NCT04711642
Collaborators
Alcon Research
Investigators
Principal Investigator: Luis Montecinos Buneder, MD Fundacion Oftalmologica Los Andes Principal Investigator: Juan Stoppel Ortiz, MD Fundacion Oftalmologica Los Andes Study Chair: Felipe Valenzuela Santana, MD Fundación Oftalmológica Los Andes Principal Investigator: Cristobal Loezar Hernandez, MD Fundacion Oftalmologica Los Andes